万泽股份：珠海生物医药研发总部及产业化基地已全面进入设施设备调试、验证阶段

Group 1 - The company is constructing dual bases in the north and south as part of its strategic planning to ensure existing product capacity meets market demand while preparing for future growth and new product introductions [1] - The dual base layout is expected to effectively reduce transportation costs [1] - The Zhuhai biopharmaceutical R&D headquarters and industrialization base have entered the facility equipment debugging and verification stage, while the Inner Mongolia Shachiqi new plant is in the procurement, installation, and purification engineering phase [1] Group 2 - Once the dual bases are completed, the company's existing production capacity for Jindongqi and Dingjunsheng is expected to increase by 50% to meet the growing market demand [1]